NCT07449195

Brief Summary

The purpose of this study is to compare two devices used for optical coherence tomography (OCT). OCT is a noninvasive imaging (scanning) method that uses reflected light to create pictures of the back of the eye, and doctors can use OCT to detect and monitor different types of cancer

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
60

participants targeted

Target at P25-P50 for not_applicable

Timeline
19mo left

Started Feb 2026

Typical duration for not_applicable

Geographic Reach
1 country

7 active sites

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress22%
Feb 2026Feb 2028

First Submitted

Initial submission to the registry

February 27, 2026

Completed
Same day until next milestone

Study Start

First participant enrolled

February 27, 2026

Completed
5 days until next milestone

First Posted

Study publicly available on registry

March 4, 2026

Completed
2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 27, 2028

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

February 27, 2028

Last Updated

May 13, 2026

Status Verified

May 1, 2026

Enrollment Period

2 years

First QC Date

February 27, 2026

Last Update Submit

May 12, 2026

Conditions

Ocular Tumor

Keywords

Ocular Tumors25-314Memorial Sloan Kettering Cancer Center

Outcome Measures

Primary Outcomes (2)

  • Image quality for participants

    Evaluated by next-generation swept-source OCT versus standard OCT for imaging of the eye and any relevant ocular tumors.

    Up to 1 year

  • Field of view for participants

    Evaluated by next-generation swept-source OCT versus standard OCT for imaging of the eye and any relevant ocular tumors.

    Up to 1 year

Study Arms (1)

Participants with Ocular Tumor

EXPERIMENTAL

Participants will have at least 1 eye that has an intraocular or ocular surface tumor.

Diagnostic Test: Intalight Dream OCTDiagnostic Test: Heidelberg Spectralis OCT

Interventions

Intalight Dream OCTDIAGNOSTIC_TEST

This is a next-generation swept-source device that has a faster imaging speed and higher sensitivity than the previous generation of frequency-domain OCT devices, which serve as the current standard of care devices.

Participants with Ocular Tumor
Heidelberg Spectralis OCTDIAGNOSTIC_TEST

This is the standard of care for optical imaging.

Participants with Ocular Tumor

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Age ≥18 years.
  • At least 1 eye that has an intraocular or ocular surface tumor.
  • The presence of a natural crystalline lens or intraocular lens.
  • Pupils that can dilate up to at least 3 mm in the study eyes.
  • The absence of opaque natural crystalline lenses or the presence of any ocular disease that prevents the view of the retina for imaging.
  • Patients must be able to fixate on the imaging target.
  • Patients must be able to sit still for a period of time (approximately 2 minutes).

You may not qualify if:

  • Does not meet ALL of the above conditions

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (7)

Memorial Sloan Kettering at Basking Ridge (Consent Only)

Basking Ridge, New Jersey, 07920, United States

RECRUITING

Memorial Sloan Kettering Monmouth (Consent only)

Middletown, New Jersey, 07748, United States

RECRUITING

Memorial Sloan Kettering Bergen (Consent Only)

Montvale, New Jersey, 07645, United States

RECRUITING

Memorial Sloan Kettering Cancer Center @ Suffolk-Commack (Consent only)

Commack, New York, 11725, United States

RECRUITING

Memorial Sloan Kettering Westchester (Consent Only)

Harrison, New York, 10604, United States

RECRUITING

Memorial Sloan Kettering Cancer Center (All Protocol Activites)

New York, New York, 10065, United States

RECRUITING

Memorial Sloan Kettering Cancer Center @ Nassau (Consent only)

Uniondale, New York, 11553, United States

RECRUITING

Related Links

MeSH Terms

Conditions

Eye Neoplasms

Condition Hierarchy (Ancestors)

Neoplasms by SiteNeoplasmsEye Diseases

Study Officials

  • Jasmine Francis, MD

    Memorial Sloan Kettering Cancer Center

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Jasmine Francis, MD

CONTACT

212-639-7266francij1@mskcc.org

David Abramson, MD

CONTACT

212-639-7232abramsod@mskcc.org

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
DIAGNOSTIC
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

February 27, 2026

First Posted

March 4, 2026

Study Start

February 27, 2026

Primary Completion (Estimated)

February 27, 2028

Study Completion (Estimated)

February 27, 2028

Last Updated

May 13, 2026

Record last verified: 2026-05

Data Sharing

IPD Sharing
Will share

Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials. The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required. Requests for deidentified individual participant data can be made following one year after publication and for up to 36 months later. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Requests may be made to: crdatashare@mskcc.org.

Locations

US(7)